Amlodipine

CLINICAL USE

Calcium-channel blocker:

  • Hypertension
  • Angina prophylaxis

    DOSE IN NORMAL RENAL FUNCTION

    5–10 mg daily

    PHARMACOKINETICS

  • Molecular weight                           :
    567.1 (as besilate)
  • %Protein binding                           :
    >95
  • %Excreted unchanged in urine     :
  • <10           :
  • Volume of distribution (L/kg)       :
    20
  • half-life – normal/ESRD (hrs)      :
    35–50/50

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           :
    Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :
    Not dialysed. Dose as in normal renal function
  • HD                     :
    Not dialysed. Dose as in normal renal function
  • HDF/high flux   :
    Unlikely to be dialysed. Dose as in
    normal renal function
  • CAV/VVHD      :
    Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • Anaesthetics: enhanced hypotensive effect
  • Antihypertensives: enhanced hypotensiveeffect; increased risk of first dose
    hypotensive effect of post-synaptic alpha-
    blockers
  • Antivirals: concentration possiblyincreased by ritonavir
    Theophylline: possibly increased

    theophylline concentration

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Amlodipine is extensively metabolised to

    inactive metabolites

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia